Gabapentin Capsule
Product Images NDC 55700-949

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 55700-949). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quality Care Products, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (1)

Gabapentin 100 mg oral capsules label showing a bottle containing 120 capsules. The label indicates the product is packaged and distributed by Quality Care Products, LLC, with storage instructions and a warning to keep out of children's reach. The capsules are described as white. Manufacturer is ScieGen Pharmaceuticals, Inc.*

FDA Label Image

Image Description (2)

Gabapentin 300 mg oral capsules, packaged and distributed by Quality Care Products, LLC. The label indicates a package size of 120 capsules, with additional information such as GTIN, NDC 55700-0949-01, and storage instructions to keep the product at 68 to 77 degrees Fahrenheit. The capsules are described as yellow. Manufacturer is ScieGen Pharmaceuticals, Inc., Hauppauge, NY.*

FDA Label Image

Figure 1 (Image 01)

A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks, while the y-axis represents mean pain scores. The graph highlights a 4-week dose titration period followed by a 4-week fixed dose period, showing a decline in pain scores for Gabapentin compared to placebo.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting mean pain scores over a 7-week period for placebo and two gabapentin dosage groups (1800 mg/day and 2400 mg/day). The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows the mean pain score. Gabapentin groups show a decline in pain scores compared to placebo over time.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) dosages in two studies. It shows percentages of responders with significant p-values indicated for GBP at various dosages (3600 mg in Study 1; 1800 mg and 2400 mg in Study 2) compared to placebo.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A formula depicting the calculation of creatinine clearance (CLCr), which includes age, weight, serum creatinine, and adjustment for female patients. This mathematical expression is typically used in clinical contexts to estimate kidney function.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin, showing a cyclohexane ring bonded to an amino group and a carboxymethyl group.*

FDA Label Image

Image-09 (Image 09)

A scatter plot comparing percentage differences against daily doses in mg for gabapentin across three different studies, labeled a, b, and c. The x-axis shows daily dose ranges from 600 to 1800 mg, and the y-axis shows percentage difference from 2% to 22%. Data points are marked with distinct symbols for each study.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.